Bispecific Antibodies and CAR-T Cells: Dueling Immunotherapies for Large B Cell Lymphomas

Despite recent advances in frontline therapy for diffuse large B-cell lymphoma (DLBCL), at least a third of those diagnosed still will require second or further lines for relapsed or refractory disease.